Strategy+ Advises Pfizer (NYSE: PFE) on Acquisition of Array Biopharma (NASDAQ: ARRY)

By

Strategy+ originated and advised Pfizer (NYSE: PFE) on the $11.4 Billion acquisition of Array Biopharma (NASDAQ: ARRY).

Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Array BioPharma Inc. (NASDAQ: ARRY), a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. The definitive merger agreement was announced June 17, 2019. Pfizer agreed to acquire Array for a total enterprise value of $11.4 Billion in cash.

‍

Read the transaction press release

Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

strategyadd.com (the “Strategy Group LLC Website”) is a website operated by Strategy Group LLC, a privately held Florida limited liability company. Strategy Group LLC is not a registered broker-dealer. Strategy Group LLC provides strategic advisory and consulting services strictly in connection with mergers and acquisitions and capital raising. Strategy Group LLC does not act as a broker-dealer, does not engage in securities transactions, and does not receive transaction-based compensation. Strategy Group LLC’s services are limited to strategic advisory, and it does not perform or facilitate securities sales or trades.